The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
The test detects and differentiates respiratory syncytial virus and human metapneumovirus on the firm's Solana rapid molecular platform.
The assay runs on the Panther Fusion system, which combines transcription-mediated amplification, real-time TMA, and real-time PCR with full sample-to-result automation.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.